Cancer Biology & Genetics Program
The Craig Thompson Lab
Research
Professor
The Thompson laboratory has proposed that the basis of metazoan cell survival is determined by the inability of cells to take up nutrients in a cell-autonomous fashion. This hypothesis was formulated to explain how multicellularity might have arisen during evolution. We believe the lack of a cell-intrinsic mechanism to regulate nutrient uptake provides the first and most fundamental barrier to cell transformation.
Featured News
Publications Highlights
People
Craig B. Thompson, MD
Professor
- Craig Thompson studies molecular signaling pathways that regulate nutrient uptake and the role these pathways play in the regulation of cell growth and survival.
- MD, University of Pennsylvania
- [email protected]
- Email Address
Members
Lab Alumni
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Get in Touch
-
Lab Head Email
-
Lab Phone
-
Lab Fax
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Craig B. Thompson discloses the following relationships and financial interests:
-
Albert and Mary Lasker Foundation
Professional Services and Activities -
Charles River Laboratories
Equity; Fiduciary Role / Position -
Economic Club of New York
Fiduciary Role / Position -
Elsevier
Intellectual Property Rights
-
Hakluyt & Company
Professional Services and Activities -
Howard Hughes Medical Institute
Professional Services and Activities -
Regeneron Pharmaceuticals, Inc.
Equity; Fiduciary Role / Position
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].